MINI-REVIEW ON ANTI-BREAST CANCER SYNTHETIC COMPOUNDS
Keywords:
Anti breast cancer drug, Functional group, Effective cell lines, MCF-7, MDA-MB-231, HeLa and HT29 cell linesAbstract
The most frequently diagnosed malignancy and the second largest cause of cancer-related death in women is breast cancer (BrCa). There have been alarming rises in BrCa therapy requests. For the treatment and prevention of BrCa, scientists are turning to agents with more efficacies, such as synthetic compounds, as the majority of chemotherapeutic medicines are linked to drug resistance, cancer relapse, and adverse effects. Selected simple synthetic compounds inhibit metastasis and stimulate apoptosis, slowing the spread of cancer. Therefore, these compounds have the ability to inhibit BrCa advancement, thereby raising patient survival rates and lowering the number of deaths brought on by BrCa. We list chemical compounds that have been shown in numerous studies to have anti-cancer actions on BrCa cells in this review. These organic compounds stimulate cell death, limit BrCa formation, and slow the growth of cancerous cells. We draw the conclusion that, in addition to therapeutic approaches, synthetic compounds are efficient, effective, and promising agents in the development of anti-breast cancer drug.
References
Chimento A, Saturnino C, Iacopetta D, Mazzotta R, Caruso A, Plutino MR, Mariconda A, Ramunno A, Sinicropi MS, Pezzi V, Longo P. Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes. Bioorganic & medicinal chemistry. 2015 Nov 15;23(22):7302-12.
El-Sharief AM, Ammar YA, Belal A, El-Sharief MA, Mohamed YA, Mehany AB, Ali GA, Ragab A. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers. Bioorganic chemistry. 2019 Apr 1;85:399-412.
Mrozek-Wilczkiewicz A, Malarz K, Rejmund M, Polanski J, Musiol R. Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety. European Journal of Medicinal Chemistry. 2019 Jun 1;171:180-94.
Hanif M, Babak MV, Hartinger CG. Development of anticancer agents: wizardry with osmium. Drug Discovery Today. 2014 Oct 1;19(10):1640-8.
Havrylyuk D, Kovach N, Zimenkovsky B, Vasylenko O, Lesyk R. Synthesis and anticancer activity of isatin‐based pyrazolines and thiazolidines conjugates. Archiv der Pharmazie. 2011 Aug;344(8):514-22.
Ragab FA, Abou-Seri SM, Abdel-Aziz SA, Alfayomy AM, Aboelmagd M. Design, synthesis and anticancer activity of new monastrol analogues bearing 1, 3, 4-oxadiazole moiety. European Journal of Medicinal Chemistry. 2017 Sep 29;138:140-51.
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast cancer research and treatment. 2014 Apr;144:223-32.
Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. Journal of medicinal chemistry. 2011 Jan 13;54(1):3-25.
Dawood KM, Gomha SM. Synthesis and Anti‐cancer Activity of 1, 3, 4‐Thiadiazole and 1, 3‐Thiazole Derivatives Having 1, 3, 4‐Oxadiazole Moiety. Journal of Heterocyclic Chemistry. 2015 Sep;52(5):1400-5.
Hamad M. Alkahtani, Ashraf N. Abdalla, Ahmad J. Obaidullah, Mohammed M. Alanazi, Abdulrahman A. Almehizia, Mashael G. Alanazi, Ahmed Y. Ahmed, Osama I. Alwassil, Hany W. Darwish, Alaa A.-M. Abdel-Aziz, Adel S. El-Azab. "Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitorsof EGFR/HER2." Bioorganic Chemistry (2019).
Alkahtani HM, Alanazi MM, Aleanizy FS, Alqahtani FY, Alhoshani A, Alanazi FE, Almehizia AA, Abdalla AN, Alanazi MG, El-Azab AS, Alaa AM. Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5, 5-diphenylimidazolidine-2, 4-dione derivatives: Molecular docking studies. Saudi Pharmaceutical Journal. 2019 Jul 1;27(5):682-93.
Santos IS, Guerra FS, Bernardino LF, Fernandes PD, Hamerski L, Silva BV. A facile synthesis of novel isatinspirooxazine derivatives and potential in vitro anti-proliferative activity. Journal of the Brazilian Chemical Society. 2019;30:198-209.
Abbas I, Gomha S, Elaasser M, Bauomi M. Synthesis and biological evaluation of new pyridines containing imidazole moiety as antimicrobial and anticancer agents. Turkish Journal of Chemistry. 2015;39(2):334-46.
Vine KL, Matesic L, Locke JM, Skropeta D. Recent highlights in the development of isatin-based anticancer agents. Adv. Anticancer Agents Med. Chem. 2013 Jun 14;2:254-312.
Kater L, Claffey J, Hogan M, Jesse P, Kater B, Strauss S, Tacke M, Prokop A. The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells. Toxicology in Vitro. 2012 Feb 1;26(1):119-24.
Yin L, Hu Q, Hartmann RW. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks. Journal of medicinal chemistry. 2013 Jan 24;56(2):460-70.
Fares M, Eldehna WM, Abou‐Seri SM, Abdel‐Aziz HA, Aly MH, Tolba MF. Design, synthesis and in vitro antiproliferative activity of novel isatin‐quinazoline hybrids. Archiv der Pharmazie. 2015 Feb;348(2):144-54.
Ahsan MJ, Choupra A, Sharma RK, Jadav SS, Padmaja P, Hassan M, Al-Tamimi A, Geesi MH, Bakht MA. Rationale design, synthesis, cytotoxicity evaluation, and molecular docking studies of 1, 3, 4-oxadiazole analogues. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2018 Jan 1;18(1):121-38.
Agarwal M, Singh V, Sharma SK, Sharma P, Ansari MY, Jadav SS, Yasmin S, Sreenivasulu R, Hassan MZ, Saini V, Ahsan MJ. Design and synthesis of new 2, 5-disubstituted-1, 3, 4-oxadiazole analogues as anticancer agents. Medicinal Chemistry Research. 2016 Oct;25:2289-303.
Harding MM, Mokdsi G. Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Current medicinal chemistry. 2000 Dec 1;7(12):1289-303.
Rana P, Murthy RS. Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism. Drug delivery. 2013 Jun 1;20(5):224-35.
Kwon S, Lee Y, Jung Y, Kim JH, Baek B, Lim B, Lee J, Kim I, Lee J. Mitochondria-targeting indolizino [3, 2-c] quinolines as novel class of photosensitizers for photodynamic anticancer activity. European journal of medicinal chemistry. 2018 Mar 25;148:116-27.
Thirunavukkarasu T, Sparkes HA, Natarajan K. Quinoline based Pd (II) complexes: Synthesis, characterization and evaluation of DNA/protein binding, molecular docking and in vitro anticancer activity. Inorganica Chimica Acta. 2018 Oct 1;482:229-39.
Köprülü TK, Ökten S, Tekin Ş, Cakmak O. Biological evaluation of some quinoline derivatives with different functional groups as anticancer agents. Journal of Biochemical and Molecular Toxicology. 2019 Mar;33(3):e22260.
Hou Y, Shang C, Wang H, Yun J. Isatin–azole hybrids and their anticancer activities. Archiv der Pharmazie. 2020 Jan;353(1):1900272.
Özkay Y, Işıkdağ İ, İncesu Z, Akalın G. Synthesis of 2-substituted-N-[4-(1-methyl-4, 5-diphenyl-1H-imidazole-2-yl) phenyl] acetamide derivatives and evaluation of their anticancer activity. European journal of medicinal chemistry. 2010 Aug 1;45(8):3320-8.
Xiao Z, Lei F, Chen X, Wang X, Cao L, Ye K, Zhu W, Xu S. Design, synthesis, and antitumor evaluation of quinoline‐imidazole derivatives. Archiv der Pharmazie. 2018 Jun;351(6):1700407.
Published
Abstract Display: 102 
PDF Downloads: 41 How to Cite
Issue
Section
Copyright (c) 2023 Nishith Teraiya, Tarun .M. Patel, Parashar Modh, Archita Patel, Nidhi Dave (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
